Educational summaries on new medications and research pipelines.
Structured, plainly written updates for patients and clinicians alike.
Tirzepatide — Extended Indications
Type 2 diabetes; chronic weight management
Long-term data continue to accumulate; individualized decisions are essential.
Non-exhaustive summary intended for educational context. See references for underlying literature.
Semaglutide — Cardiovascular Outcomes
Type 2 diabetes, weight management, cardiovascular risk reduction
Cardiovascular outcome data broaden clinical use in selected populations.
Non-exhaustive summary intended for educational context. See references for underlying literature.
Bempedoic Acid
LDL-C lowering in adults with statin intolerance or insufficient response
Complementary role in a lipid-lowering strategy.
Non-exhaustive summary intended for educational context. See references for underlying literature.
Lipoprotein(a)-Targeted Therapies
Elevated Lp(a) as a residual cardiovascular risk factor
Awaiting outcome data; not currently available for routine use.
Non-exhaustive summary intended for educational context. See references for underlying literature.